Inhibrx Biosciences (INBX) has gained attention following encouraging interim data on its ozekibart treatment combined with FOLFIRI for unresectable colorectal cancer, along with positive results from a chondrosarcoma trial. The stock has surged, with a current price of $115.61, reflecting a substantial 78.88% increase over the past month and a year-to-date return of 54.06%. However, the company shows a high price-to-book ratio of 211.3x, indicating it may be overvalued compared to the biotech industry averages. Investors are now weighing the value of INBX’s clinical data against its substantial financial losses and limited revenue, leading to uncertainty about its future market pricing and clinical risks.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inbx/inhibrx-biosciences/news/a-look-at-inhibrx-biosciences-inbx-valuation-after-recent-oz
